Phase II clinical trial assessing MP-101
Latest Information Update: 17 Sep 2021
At a glance
- Drugs MP-101 Metys Pharmaceuticals (Primary)
- Indications Chemotherapy-induced damage; Neuropathic pain; Peripheral neuropathies
- Focus Adverse reactions
- 17 Sep 2021 New trial record
- 07 Sep 2021 According to Novaremed media release, Novaremed has acquired Metys Pharmaceuticals.
- 07 Sep 2021 According to Novaremed media release, this trial is expected to start in the first quarter of 2023.